Celularity

Celularity ROA

The Return on Assets (ROA) of Celularity (CELU) as of Nov 14, 2026 is -85.53 %. In the previous year, Return on Assets (ROA) was -43.63 % — a change of 96.03% (lower).

ROA

-85.53 %

YoY

96.03%

Last updated:

In 2025, Celularity's return on assets (ROA) was -85.53 %, a 96.03% increase from the -43.63 % ROA in the previous year.

The Celularity ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-4.44 USD
Jan 1, 2019
-40.63 USD
Jan 1, 2020
-48.31 USD
Jan 1, 2021
-24.18 USD
Jan 1, 2022
3.54 USD
Jan 1, 2023
-136.42 USD
Jan 1, 2024
-43.63 USD
Jan 1, 2025
-85.53 USD
The Celularity ROA history
YEARROAYoY
-85.53 %+96.03%
-43.63 %-68.02%
-136.42 %-3,955.26%
3.54 %-114.64%
-24.18 %-49.96%
-48.31 %+18.91%
-40.63 %+814.24%
-4.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity, Inc. develops off-the-shelf placental-derived allogeneic cell therapies for cancer and immune and infectious diseases. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include CAR-T cells, natural killer cells, mesenchymal-like adherent stromal cells, and exosomes targeting cancer, infectious, and degenerative diseases. The company's cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy targeting B-cell malignancies. pEXO-001 is a placental-derived exosome therapy in development. The company generates revenue through the development and commercialization of its cell therapy programs. The Cell Therapy segment focuses on developing therapies for cancer, while the Degenerative Disease segment targets conditions like osteoarthritis and neurodegenerative disorders. BioBanking involves the collection and storage of placental tissue for future therapeutic use. The primary buyers of these therapies are healthcare providers and hospitals treating patients with cancer, immune disorders, and infectious diseases. Celularity's product portfolio includes CYCART-19 for B-cell malignancies, CYNK-001 for solid tumors, and pEXO-001 for regenerative medicine. The company's target market segments are patients with cancer, immune disorders, and infectious diseases. The Degenerative Disease segment specifically addresses conditions such as osteoarthritis and neurodegenerative disorders through its cell therapy programs. BioBanking supports the company's research and development by providing a source of placental-derived cells for therapeutic development. Celularity is one of the most popular companies on Eulerpool.

ROA Details

Understanding Celularity's Return on Assets (ROA)

Celularity's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Celularity's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Celularity's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Celularity’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Celularity stock

Return on Assets (ROA) of Celularity is -85.53 % in 2025.

Return on Assets (ROA) of Celularity changed from -43.63 % to -85.53 %, representing a 96.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Celularity since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Celularity with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Celularity

All Key Metrics — Celularity